MAP2K7 and neoplasm: The co-administration of FGFR inhibitor and MEK inhibitor (trametinib) exhibited a potent synergistic effect, targeting pFGFR, pAkt, and pErk, thereby effectively inhibiting tumor organoid proliferation.